Member Database

Jiaqi Shi, MD, PhD


Clinical Associate Professor

Dr. Jiaqi Shi received her M.D. and Ph.D. from Xiangya School of Medicine at Central South University, where she studied medical genetics and gene therapy. Dr. Shi pursued postdoctoral work in melanoma and pancreatic cancer biology at the University of Arizona, supported by NCI/NIH R03 awards. After Pathology residency training at the University of Arizona and the University of Michigan, Dr. Shi pursued a Gastrointestinal Pathology fellowship training under the guidance of Dr. Henry Appelman at the University of Michigan. Dr. Shi was the first to describe the essential roles of a translation initiation factor, eIF3f, in apoptosis, translational regulation, and pancreatic cancer development. She was also the first to provide important insight into extracellular DNA in metastasis and histone modification enzymes, KDM6A and KMT2D, in pancreatic tumorigenesis and immune environment. Dr. Shi has received a Bristol-Myers Squibb Oncology Scholar-in-Training Award from the American Association for Cancer Research (AACR), a Benjamin Castleman Award from the United States and Canadian Academy of Pathology (USCAP), an NCI Mentored Clinical Scientist Research Career Development Award (K08), and an NCI MERIT (Method to Extend Research in Time) Award (R37). She serves as a standing member of an NIH study section, a reviewer for the National Institute for Health Research (NIHR) of the UK, and an Abstract Review Board member of USCAP and the American Gastroenterological Association (AGA). Dr. Shi is also an Editorial Board Member of Modern Pathology and World Journal of Gastrointestinal Oncology, a Reviewer Board Member of Cancers, and an Associate Editor of Frontiers in Oncology.


Not started yet

University Affiliation(s)

Rogel Cancer Center

Research Area(s)

Basic and Translational cancer research


  • Funded by: SHI, Jiaqi
  • Funded by: SHI, Jiaqi
  • Principal investigator of: Defining the immune tumor microenvironment of pancreatic ductal adenocarcinomas carrying COMPASS-like complex gene alterations
View all grants